TickerFacts.

Immunocore Holdings plc (IMCR): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$10.71M
Year ended 2025-12-31
-$34.96M
Trailing 12 months to 2026-06-30
$26.06M2021-12-31: -$143.11M2022-12-31: -$49.21M2023-12-31: $2.94M2024-12-31: $26.06M2025-12-31: -$10.71M-$10.71M
2021-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$10.71Mn/m2026-02-25, From 2025-01-01
2024-12-31$26.06M+786.4%2026-02-25, From 2024-01-01
2023-12-31$2.94Mn/m2026-02-25, From 2023-01-01
2022-12-31-$49.21Mn/m2025-02-26, From 2022-01-01
2021-12-31-$143.11Mn/a2024-02-28, From 2021-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Immunocore Holdings plc (IMCR)2025-12-31-$10.71Mn/m
Krystal Biotech, Inc. (KRYS)2025-12-31$200.87M+62.7%
Twist Bioscience Corp (TWST)2025-09-30-$47.63Mn/m
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31-$12.45Mn/m
ADMA Biologics, Inc. (ADMA)2025-12-31$50.40M-57.5%
Adaptive Biotechnologies Corp (ADPT)2025-12-31-$45.99Mn/m
Vericel Corp (VCEL)2025-12-31$51.91M-10.8%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31-$302.41Mn/m
Vaxart, Inc. (VXRT)2025-12-31$7.71Mn/m

Compare IMCR, KRYS, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗